Showing results (391-400 of 832) with videos related to
Sort By:
Pageof 84
Diabetes, Obesity & Metabolism|February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathyHiddo J L Heerspink, Dennis L Andress, George Bakris, et al.Diabetes, Obesity & Metabolism|April 1, 2018
Baseline characteristics and enrichment results from the SONAR trialHiddo J L Heerspink, Dennis L Andress, George Bakris, et al.Diabetes, Obesity & Metabolism|December 17, 2016
Comparison of exposure response relationship of atrasentan between North American and Asian populationsHiddo J L Heerspink, Hirofumi Makino, Dennis Andress, et al.Clinical Pharmacology and Therapeutics|December 18, 2020
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney DiseaseJeroen V Koomen, Jasper Stevens, George Bakris, et al.Clinical Journal of the American Society of Nephrology : CJASN|December 2, 2021
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized TrialSimke W Waijer, Ron T Gansevoort, George L Bakris, et al.Journal of the American Society of Nephrology : JASN|February 13, 2009
Expression, localization, and function of the thioredoxin system in diabetic nephropathyAndrew Advani, Richard E Gilbert, Kerri Thai, et al.Diabetes|October 27, 2006
Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin geneNathalie Vionnet, David Tregouët, Gbenga Kazeem, et al.Current Eye Research|June 14, 2006
An extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) system for grading of diabetic macular edema in the Astemizole Retinopathy TrialThomas W Gardner, Birgit Sander, Michael L Larsen, et al.Journal of the American Society of Nephrology : JASN|April 12, 2014
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyDick de Zeeuw, Blai Coll, Dennis Andress, et al.Diabetes Care|August 30, 2023
Declining Incidence Rates of Distal Symmetric Polyneuropathy in People With Type 1 and Type 2 Diabetes in Denmark, With Indications of Distinct Patterns in Type 1 DiabetesHatice Isik Mizrak, Tine Willum Hansen, Peter Rossing, et al.Pageof 84